Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14 ...

Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc William Wood; Analyst; B. Riley Securities Jack Allen; ...

Universal Cells had developed a distinctive method of modifying pluripotent stem cells ... For each treatment, scientists can create a bank of universal donor cells, and a desired group of ...

The ability to reprogram mature, differentiated cells into induced pluripotent stem cells (iPSCs ... stock that can cover almost the entire Japanese population. iPSCs in this bank were obtained by the ...

The expansion of patient population and reach is well supported by the ability to produce FT819 in large quantities from a master cell bank, ensuring consistent ... Human induced pluripotent stem ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...

Inhibition of PRC2 enables self-renewal of blastoid-competent naive pluripotent stem cells from chimpanzee. Cell Stem Cell , 2025; 32 (4): 627 DOI: 10.1016/j.stem.2025.02.002 Cite This Page : ...